US hospitals ask for a single AI rule, not a patchwork of 50 state laws

By Chief Healthcare Executive · September 16, 2026.

The outlet runs, in its briefs section ("Shorts"), a headline that captures a widespread position among U.S. health systems: they would rather clinical artificial intelligence be regulated under a single federal framework than under 50 different sets of state rules. It has to be said honestly: the original article offers no figures, surveys or direct quotes from any specific executive or association. It is a service item, and we treat it as such, without inflating it with details that are not there.

In general, concern about regulatory fragmentation is nothing new in healthcare. It happened with telemedicine, where each state requires its own medical license, and with data privacy after years of a federal regulatory vacuum beyond HIPAA. A hospital operating in several states, or a clinical software vendor selling into several of them, does not want to maintain different versions of the same triage or coding algorithm in order to comply with different rules at every state line. Chief Healthcare Executive itself published a piece days earlier, on September 8, on how a U.S. executive order reopens the question of who sets the standard for AI in health: the federal government, each state on its own, or the industry itself through sector certifications?

Two things that are easily conflated should be separated here. Asking for a single framework is not necessarily the same as asking for less oversight: it can legitimately mean asking for predictable oversight. But it should also be said without hedging: "give us one rule" is, in other sectors, the usual language with which industry pushes for federal preemption to shield itself from stricter state rules, such as those California, Colorado or Illinois have already advanced on AI. With no further detail in the article, we do not know which specific players are behind this position or with what exact intent, and we are not going to fill that gap with conjecture the source does not support.

What we do maintain, as an underlying thesis, is that a health system deploying AI for diagnosis, patient prioritization or bed management needs clear, stable rules to invest with confidence, and that certainty is compatible with demanding safety standards; the two are not opposing goals. The long-term horizon does not change because of this regulatory debate: reliable clinical AI is a step toward faster, cheaper diagnoses and, over time, toward diseases that are chronic today ceasing to be so. But that future is built with solid, verifiable governance, not with the mere absence of rules dressed up as administrative efficiency.